Teacher Retirement System of Texas Acquires 1,180 Shares of Protagonist Therapeutics, Inc. $PTGX

Teacher Retirement System of Texas grew its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 9.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 13,205 shares of the company’s stock after purchasing an additional 1,180 shares during the period. Teacher Retirement System of Texas’ holdings in Protagonist Therapeutics were worth $730,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in PTGX. Bessemer Group Inc. increased its position in Protagonist Therapeutics by 171.0% during the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after buying an additional 318 shares in the last quarter. Hsbc Holdings PLC grew its stake in shares of Protagonist Therapeutics by 4.1% in the first quarter. Hsbc Holdings PLC now owns 8,458 shares of the company’s stock worth $405,000 after acquiring an additional 330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Protagonist Therapeutics by 16.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,394 shares of the company’s stock valued at $132,000 after acquiring an additional 340 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Protagonist Therapeutics by 0.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock worth $1,810,000 after purchasing an additional 348 shares during the last quarter. Finally, CWM LLC raised its position in shares of Protagonist Therapeutics by 201.5% in the 2nd quarter. CWM LLC now owns 609 shares of the company’s stock worth $34,000 after purchasing an additional 407 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Down 0.3%

PTGX opened at $79.54 on Friday. The stock has a market capitalization of $4.95 billion, a price-to-earnings ratio of 128.29 and a beta of 2.22. The firm has a 50 day moving average price of $68.54 and a 200-day moving average price of $57.48. Protagonist Therapeutics, Inc. has a twelve month low of $33.31 and a twelve month high of $93.25.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The company had revenue of $4.71 million during the quarter, compared to the consensus estimate of $5.41 million. Protagonist Therapeutics had a return on equity of 6.78% and a net margin of 21.94%. As a group, analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Barclays increased their price objective on shares of Protagonist Therapeutics from $72.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday. Citigroup increased their price target on shares of Protagonist Therapeutics from $72.00 to $96.00 and gave the company a “buy” rating in a report on Friday, October 17th. Citizens Jmp raised their price target on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the company a “market outperform” rating in a research report on Friday. JPMorgan Chase & Co. upped their price objective on Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a research report on Friday. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Protagonist Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.08.

Insiders Place Their Bets

In other Protagonist Therapeutics news, Director William D. Waddill sold 12,000 shares of the firm’s stock in a transaction dated Friday, October 10th. The stock was sold at an average price of $81.62, for a total value of $979,440.00. Following the transaction, the director directly owned 5,130 shares of the company’s stock, valued at approximately $418,710.60. This trade represents a 70.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 20,000 shares of company stock valued at $1,473,440 over the last 90 days. 4.90% of the stock is currently owned by corporate insiders.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.